Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

Loading articles data…

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Readable research linked to original sources

Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

Filters

Clear all

Article type

Publication year

19172026

From yearTo year

Keyword

Active filter

Author: Nestor E Cabezudo

1 articles

Newest first

Research Article 2022-05-03CC BYCC BY allows this article to remain publicly readable here. Any reuse must still follow the recorded source terms.Free full text

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.

Natalia Vargas-Herrera, Manuel Fernández-Navarro, Nestor E Cabezudo, Percy Soto-Becerra, Gilmer Solís-Sánchez, Stefan Escobar-Agreda +5 more

BackgroundThe administration of a third (booster) dose of COVID-19 vaccines in Peru initially employed the BNT162b2 (Pfizer) mRNA vaccine. The national vaccination program started with healthcare workers (HCW) who received BBIBP-CorV (Sinopharm) vaccine as primary regimen and elderly people previously immunized with BNT162b2. This study evaluated the reactogenicity and immunogenicity of the "booster" dose in these…

medRxiv medRxiv↗

Open article record in new tab ↗

End of results

The service organizes published evidence. It does not provide medical advice.